Скачать или смотреть Wegovy FDA Approval for MASH: Novo Nordisk’s Breakthrough Liver Disease Treatment

Discover how Novo Nordisk's Wegovy (semaglutide) has received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. This video explains the significance of this first-in-class GLP-1 therapy for MASH, the details of the clinical study, and its impact on patients with moderate to advanced liver fibrosis. Learn about Wegovy’s role in the metabolic disease market and how it may change treatment options alongside diet and exercise. Stay informed on upcoming approvals in Europe and Japan and comparisons with other MASH treatments like Rezdiffra.

Keywords: Wegovy, Novo Nordisk, MASH treatment, metabolic dysfunction-associated steatohepatitis, FDA accelerated approval, GLP-1 therapy, liver disease, semaglutide, liver fibrosis, metabolic disease drugs, obesity drug, Rezdiffra, liver scarring, weight loss medication